Is initiation of atorvastatin for employees a good buy for employers?

Mayo Clinic Proceedings

Volumn 84, Issue 12, 2009, Pages 1059-1061

  Culler, Steven D ^a   Weintraub, William S ^b  

^a EMORY UNIVERSITY   (United States)

^b CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ABSENTEEISM; ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DISABILITY; DOCTOR PATIENT RELATION; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; EDITORIAL; EMPLOYEE; EMPLOYER; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH INSURANCE; HEART ARREST; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; PUBLIC HEALTH; RESUSCITATION; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME;

EID: 72949104927     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0630     Document Type: Editorial

References (6)

1. Eden J, Wheatley B, McNeil B. Sox H, eds. Institute of Medicine. Knowing What Works in Health Care: A Roadmap for the Nation. Washington, DC: National Academies Press; 2008.
2. Simpson RJ Jr, Signorovitch J, Birnbaum H, et al. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population. Mayo Clin Proc. 2009;84(12): 1065-1072.
3. Pedersen TR, Faergeman O, Kastelein JJP, et al; IDEAL Study Group. High-dose atorvastatin vs usual-dose simvatatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized clinical trial [published correction appears in JAMA. 2005;294(24):3092]. JAMA. 2005;19(294):2437-2445.
4. Krasuski RA. Primary prevention and statins: is it just about going to class [editorial]? Mayo Clin Proc. 2008;83(12):1313-1315.
5. Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151(3):206-209.
6. Gibbons RJ, Gardner TJ, Anderson JL, et al; American Heart Association Advocacy Coordinating Committee. The American Heart Association's principles for comparative effectiveness research: a policy statement from the American Heart Association. Circulation. 2009;119(22):2955-2962.